Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 1, 2022

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 21, 2022

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

GlobeNewswire November 3, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire November 1, 2022

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

GlobeNewswire November 1, 2022

Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

GlobeNewswire October 31, 2022

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

GlobeNewswire October 25, 2022

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

GlobeNewswire October 13, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire October 3, 2022

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

GlobeNewswire September 26, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire September 1, 2022

Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 1, 2022

Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million

GlobeNewswire August 3, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 1, 2022

Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

GlobeNewswire July 25, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire July 1, 2022

Paratek Pharmaceuticals' NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)

GlobeNewswire June 21, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 1, 2022

Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference

GlobeNewswire June 1, 2022

Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 16, 2022